Christoph Varenhorst

List of Publications by Year
in descending order

31	1,649	394286 19	414303 32
papers	citations	h-index	g-index

35	35	35	2862
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European Heart Journal, 2009, 30, 1744-1752.	1.0	231
2	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal, 2014, 35, 2083-2093.	1.0	171
3	Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. European Heart Journal, 2016, 37, 3335-3342.	1.0	138
4	Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study. American Heart Journal, 2016, 178, 85-94.	1.2	134
5	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2018, 11, 1437-1449.	1.1	111
6	Stent Thrombosis in New-Generation Drug-Eluting Stents in Patients With STEMI Undergoing Primary PCI. Journal of the American College of Cardiology, 2014, 64, 16-24.	1.2	110
7	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 2015, 36, 1901-1912.	1.0	107
8	Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. American Heart Journal, 2009, 157, 562.e1-562.e9.	1.2	81
9	Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2012, 60, 1623-1630.	1.2	80
10	External Validation of the DAPT Score in a Nationwide Population. Journal of the American College of Cardiology, 2018, 72, 1069-1078.	1.2	63
11	Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. European Heart Journal, 2014, 35, 969-978.	1.0	46
12	Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	45
13	Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). JACC: Cardiovascular Interventions, 2016, 9, 207-215.	1.1	43
14	Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 5-12.	1.4	40
15	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart, 2014, 100, 1762-1769.	1.2	38
16	Realâ€life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Catheterization and Cardiovascular Interventions, 2017, 90, 881-887.	0.7	35
17	Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function. Heart, 2018, 104, 1575-1582.	1.2	29
18	Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 151-157.	1.4	27

#	Article	IF	Citations
19	Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. Clinical Research in Cardiology, 2018, 107, 816-823.	1.5	21
20	Timing of percutaneous coronary intervention in patients with non-ST-elevation myocardial infarction: a SWEDEHEART study. European Heart Journal Quality of Care & Clinical Outcomes, 2017, 3, 53-60.	1.8	18
21	Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. Kidney International, 2017, 91, 216-226.	2.6	16
22	Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 2015, 170, 465-470.	1.2	11
23	Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report. American Heart Journal, 2016, 176, 78-82.	1.2	9
24	Outcomes after STEMI in old multimorbid patients with complex health needs and the effect of invasive management. American Heart Journal, 2019, 211, 11-21.	1.2	8
25	Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary interventionâ€"A case-control study. American Heart Journal, 2011, 162, 363-371.	1.2	7
26	Which Antiplatelet Agent for Whom? Which Patient Populations Benefit Most from Novel Antiplatelet Agents (Ticagrelor, Prasugrel)?. Current Cardiology Reports, 2012, 14, 486-492.	1.3	7
27	Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study. Clinical Therapeutics, 2017, 39, 1827-1839.e1.	1.1	7
28	New Method for Assessing the Effect of Driving Distance to Hospital Care. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	4
29	Caffeine and incidence of dyspnea in patients treated with ticagrelor. American Heart Journal, 2018, 200, 141-143.	1.2	4
30	Sex as a determinant of prehospital ECG in ST- and non-ST elevation myocardial infarction patients: TableÂ1. Heart, 2014, 100, 1817-1818.	1.2	2
31	SWEDEHEART-1-year data show no benefit of newer generation drug-eluting stents over bare-metal stents in patients with severe kidney dysfunction following percutaneous coronary intervention. Coronary Artery Disease, 2020, 31, 49-58.	0.3	2